Mab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation.
|
|
- Lee Wright
- 8 years ago
- Views:
Transcription
1 Mab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation.
2 Summary Monoclonal antibodies are expensive to develop and to manufacture. There is a clear need to reduce costs and manufacturing risk in order to support new chronic indications and extend their reach in the developing world. BioSolve Process is used to study different process scales, products and facility operations (multi component, multi product). In this study it is used to address some fundamental questions relating to the large scale manufacture of an antibody at 5 tonnes per year: What can current stainless steel technology deliver? Modelling in BioSolve Process shows that for a traditional six pack stainless steel facility, a cost of goods per gram of $35 can be achieved with a capital investment of $352 million into the manufacturing plant. What is the potential for modular single-use facilities? BioSolve Process shows that a modular single-use facility can deliver a comparable cost of goods at $38/g but with a 30% reduction in capital investment at $250 million, achieved by shifting cost from fixed to variable costs. Combined with faster builds and easier reconfiguration, this allows adoption of a scaleout approach that significantly reduces overall manufacturing risk. What is the potential for continuous processing facilities? BioSolve Process finally reveals that combining continuous technology with modular single use technology has the potential to reduce the capital requirement to just $80 million and a resulting cost of goods of $32/g, with the potential for even greater reductions to around $15/g. Continuous technology has the potential to reduce costs and significantly reduce risk, making it easier to widen patient access and manufacture locally. Note that quality in process test costs have been excluded, and the analysis is based on a standard three-column chromatography process. In this paper, BioSolve Process is used to analyse the case of a large-scale single product but the tool can easily be applied for different scales, product types and multi-product facilities. Subsequent studies will return to this theme and look further at quality testing strategies and the quantification of risk. If you would like to be informed when these studies are published, please register at 2
3 Analysis The largest and fastest growing segment in biopharmaceuticals is monoclonal antibodies, which are typically used to address unmet acute conditions in the developed world. These novel antibodies are expensive to develop and manufacture and, as the biopharma industry seeks to develop them for chronic indications and to extend their use into the developing world, there is an increasing requirement to substantially reduce the cost to the patient. One significant component of this cost is manufacturing. In this study, we addressed three key questions regarding manufacturing cost: 1.What can current stainless steel technology deliver? 2.What is the potential for modular single-use facilities? 3.What is the potential for continuous processing facilities? Answering these questions provides insight into the current cost of bulk drug substance in today s large scale manufacturing facilities, while also exploring the potential for state-of-the-art technologies to have an impact on manufacturing costs, both now and in the future. In the creation of this study, we used the industry standard modelling software, BioSolve Process, to address these questions. The study focuses on very large scale processes in the region of five (5) tonnes per annum of bulk antibody, targeting a large patient population in the developing world. 3
4 1 What can current stainless steel technology deliver? The current state of the art manufacturing technologies for this scale are large six pack stainless steel facilities. Determining what these facilities can deliver in terms of cost is key; a question that depends greatly on factors including bioreactor size and titres. Using the multi variable analysis tools in BioSolve Process, it was possible to model three different options at around 5000 kg/yr throughput: Option 1 Option 2 Option 3 Bioreactor size 10,000L; 7g/L 15,000L; 5g/L 20,000L; 4g/L Cost of goods $34/g $35/g $38/g Capital investment $304 million $352 million $399 million All three options compare well with smaller throughputs, which typically see cost of goods in excess of several $100/g. From a manufacturing cost perspective, the option that best represents a state of the art titre is 5g/L. Option 2 represents the required facility in stainless steel to provide 5000 kg/yr.however, the capital investment and fixed operating costs required to achieve this are significant (note that the figures above only cover direct capital investment costs). Conclusion While compelling in terms of cost of goods, this approach locks the manufacturer into a fixed technology with large overheads. If the process is not certain and if it is not known whether the product will achieve the required sales, this becomes a high-risk approach. 4
5 2 What is the potential for modular single-use facilities? When looking at the potential of using the latest modular single use technologies, the key issue is one of scale. The maximum disposable bioreactor size is 2000L, so if a scale out approach is adopted, will it give the same cost outcomes? BioSolve Process is an ideal tool for doing this type of analysis as it can quickly execute multiple process comparison analyses and assess facility fit before users make a decision. Modelling in BioSolve Process shows that approximately L bioreactors are required to meet the target throughput, which can be built in modules of 15 bioreactors. The questions then become: What is the best harvest strategy? Should the outputs be pooled? If so, which configuration is optimal: one, three, five or 15 reactors? But this is not the whole story. The rapid analysis in BioSolve Process shows that the total capital investment is $250 million for two 15 bioreactor modules. This is a significant reduction from the $352 million capital investment required by the optimum approach with current stainless steel technology and represents a key decision-point from a risk management perspective. The scenario analysis capability of BioSolve Process can provide these answers quickly. By running these six scenarios, the lowest cost of goods was seen when the bioreactors are harvested in groups of three or five. In this case, a cost of goods of $38/g was achieved, which is interesting as it shows a similar result to the traditional large scale stainless steel plant. Conclusion A modular single use approach allows the facility to be rapidly turned around for new products for minimal cost compared to a traditional stainless steel facility. In addition: The capacity build can be phased in line with the demand profile The fixed running costs are less The upfront capital is significantly reduced by about 30% The build-time to bring new capacity on board is greatly reduced The key conclusion is that taking a small scale modular build out route can produce an equivalent cost of goods, while reducing scale and upfront capital, and greatly increasing operational flexibility. We will explore the financial implications of this in a later study. 5
6 3 What is the potential for continuous processing? The final step is to examine the potential of next generation of continuous processing technologies combined with modular design and single use systems. Using the continuous processing operations available in BioSolve Process, it was possible to model a 2000L single-use bioreactor operated in perfusion mode. In this case, the relative titre (comparing perfusion titre to traditional fed-batch) is important. The base case with perfusion titres was set at 1.0g/L compared to the 5g/L for fedbatch to represent legacy processes. Recognising the significant improvements achieved using high cell density devices and modern cell retention devices, the impact of improved titres up to 7.0g/L was considered. The cost of cell culture media, which is a major cost component in legacy perfusion processes, was also considered. Continuous processing can continue to be improved by targeting media cost reduction and also through recognition that titres are likely to improve significantly as cell line productivity and cell density in the bioreactor are increased. BioSolve Process enables examination of these factors in detail using the product s sensitivity analysis tools. In this case, titre improvements combined with reduced media costs were considered. This analysis shows that it should be realistic within a titre range of 2 g/l to achieve a target cost of goods in the $15/g to $20/g range at 5 tonnes per annum with continuous operations. In addition, there is a real opportunity to get between 10 to 15 g/l with titres above 4 g/l and optimised media costs. When looking at the legacy titre and the modular build, BioSolve Process shows that a cost of goods of $32/g can be achieved for an upfront capital investment of about $80 million. This is a significant improvement on the baseline stainless steel facility results, delivering a 10% reduction in cost of goods and a 73% reduction in upfront capital. More potential savings can be found when cost distribution by category is analysed, showing that media and resin costs dominate, representing 47% of the cost of goods. Conclusion Of course, for a new technology like continuous processing there are many unknowns, but BioSolve Process demonstrates the significant potential to be gained from marrying continuous technologies with portable modular build. This technology has the potential to radically change the nature of large-scale biomanufacturing. Access to this knowledge through BioSolve Process can make it easier for the industry to widen patient access and implement local manufacturing. 6
7 Background Biopharm has over 15 years experience in assessing the impact of new technologies and process options in the manufacture of biopharmaceuticals. We work with all the key stakeholders suppliers, innovators, academics and the major manufacturers. As a consequence, not only are we made aware of new innovative technologies early on, we have unparalleled insight into their impact on process and manufacturing from an operational and economic perspective. This experience has helped us shape our modelling package, BioSolve Process, and to embed in it our collective experience. BioSolve Process is accepted by the bioprocessing community as the standard for analysis of innovation. Our users feedback helps shape the product, making it more relevant with every update. BioSolve s modelling framework has demonstrated its flexibility as successive innovations have been readily incorporated in the platform. Milestone achievements include: All the major transgenic players have used Biopharm to model their technologies from corn and animals to eggs Alternatives to protein A were being explored by Biopharm as far back as 2005 Biopharm is recognised for supplying a coherent analysis of the impact of single use technology from 2002 until today Since investigations into the impact of continuous processing started in 2008 Biopharm has been working closely with many of the leading companies, users and suppliers During this period Biopharm has worked with users and suppliers to understand the implications of new process routes, Pichia, cell therapy, gene therapy, vaccines etc. In 2012 the industry recognised Biopharm founder Andrew Sinclair s contribution by nominating him for thought leader of the decade in the area of process knowledge management. In 2014 he was elected by his industry peers to become a Fellow of the Royal Academy of Engineering BioSolve software is now accepted by many leading companies as a means of ensuring a consistent approach to innovation and process analysis. This is achieved by using the platform s ability to standardise and control data sets and methods. Biopharm s experience and knowledge of the platform means we are able to analyse and assess technologies and processes in an efficient and cost effective manner. 7
8 Biopharm supports biopharma innovators across the globe. Here are 3 ways to connect with us: Tel: info@biopharmservices.com Copyright 2014 Biopharm Services Limited. All rights reserved. Biopharm, BioSolve and associated logos are trademarks of Biopharm Services Limited. All other trademarks are the property of their respective owners. All Biopharm products and services are subject to continuous development. We reserve the right to alter technical specifications without prior notice.
Biomanufacturing Vision for the Future
Biomanufacturing Vision for the Future Shou-Bai Chao, Ph.D. Senior Vice President Global Manufacturing and Technical Operations MedImmune (a Div of AstraZeneca) NIPTE/FDA Research Conference Future of
More informationEden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
More informationEconomical Approaches to Meeting Global Demand for High Value Biopharmaceuticals
Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Howard L. Levine and Susan Dana Jones BPI Europe 2013 Apr 17-18, 2013 Dusseldorf, Germany BioProcess Technology Consultants
More informationBuilding a business case for a fully continuous biomanufacturing platform
Building a business case for a fully continuous biomanufacturing platform Sol Pompe disease Argentina Integrated Continuous Biomanufacturing Jason Walther 23 October 2013 www.genzyme.com Fully continuous
More informationVaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010
Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it
More informationAccelerating drug development to FTIH: Potential of new expression technologies
Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum
More informationBiopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities
1 Biopharmaceutical Perspectives of Outsourcing: what are supply chain management issues and opportunities Presented by Dr. Philipp Hess Supply Chain Management Issues and Opportunities 2 1. How do we
More informationSingle-Use Bioreactors Meeting BioPharma Needs for Lower Operating Cost and Faster Time to Market
Single-Use Bioreactors Meeting BioPharma Needs for Lower Operating Cost and Faster Time to Market White Paper White Paper Single-use bioreactors meeting biopharma needs for lower operating cost and faster
More informationOne of the greatest challenges facing biopharmaceutical
Monoclonal Antibody Manufacturing Strategies for the 21st Century James Blackwell, Ph.D., MBA Sr. Consultant Thomas Ransohoff, VP and Sr. Consultant Howard L. Levine, Ph.D., President and Principal Consultant
More informationThe Importance of Developing a High Yield of Product
European Antibody Congress Lyon, 3 rd November 2005 The Importance of Developing a High Yield of Product John Birch, Lonza Biologics plc Monoclonal Antibodies A Success Story Fastest growing segment of
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationA World of Biomanufacturing: Shortages or Global Glut?
A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationThe authors: Howard L. Levine, Ph.D., President and Founder. Thomas C. Ransohoff, Senior Consultant
The authors: Howard L. Levine, Ph.D., President and Founder Dr. Levine has over 20 years of experience in the biopharmaceutical industry. Prior to founding BioProcess Technology Consultants to provide
More informationHigh yield antibody production in a disposable WAVE Bioreactor
High yield antibody production in a Process intensification using perfusion culture Christian Kaisermayer 1, Jianjun Yang 2 1 GE Healthcare Europe GmbH, Vienna, Austria (Christian.Kaisermayer@ge.com),
More informationMonoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.
Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided
More informationFlexibility in a Biotech Manufacturing Facility: An Options Analysis for Monoclonal Antibody Production
Flexibility in a Biotech Manufacturing Facility: An Options Analysis for Monoclonal Antibody Production ESD.71 Engineering Systems Analysis for Design Professor Richard de Neufville December 8, 2011 EXECUTIVE
More informationMultiple Products in a Monoclonal Antibody S88.01 Batch Plant
Presented at the World Batch Forum North American Conference Chicago, IL May 16-19, 2004 900 Fox Valley Drive, Suite 204 Longwood, FL 32779-2552 +1.407.774.0207 Fax: +1.407.774.6751 E-mail: info@wbf.org
More informationManufacturing processes for
Single-Use, Continuous- Countercurrent, Multicolumn Chromatography Marc Bisschops, Lynne Frick, Scott Fulton, and Tom Ransohoff Reprinted with permission from BioProcess International 7(6) (June 2009)
More informationNext-Generation Facilities for Monoclonal Antibody Production
Advancing Development & Manufacturing Facilities Next-Generation Facilities for Monoclonal Antibody Production Niels Guldager ELECTRONICALLY REPRINTED FROM JULY 2009 The biopharmaceutical industry faces
More informationTransgenic technology in the production of therapeutic proteins
Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.
More informationTable of Contents. Presented by
Improving Markets, Services, and Technologies Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com
More information7 things to ask when upgrading your ERP solution
Industrial Manufacturing 7 things to ask when upgrading your ERP solution The capabilities gap between older versions of ERP designs and current designs can create a problem that many organizations are
More informationOverview of Upstream and Downstream Processing of Biopharmaceuticals
Overview of Upstream and Downstream Processing of Biopharmaceuticals Ian Marison Professor of Bioprocess Engineering and Head of School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
More informationBiopharm Roundtable. 1. What, in your opinion, is currently the single largest trend with respect to biopharmaceutical outsourcing and manufacture?
BIOPHARM ROUNDTABLE Biopharm Roundtable Morrey Atkinson Vice President, R&D Cook Pharmica Peter Soelkner Managing Director Vetter Pharma-Fertigung GmbH & Co. KG Johannes Reiter Cooperations Manager Sandoz
More informationHow To Develop A Cell Line
Advances in The Development of Biopharmaceuticals The application of modern technologies and services to the development of Biopharmaceutical processes Dr Jonathan H Dempsey Process Science Fellow Invitrogen
More informationWelcome to the Launch of Biocon s Breakthrough Innovation. For Psoriasis. Treatment
Welcome to the Launch of Biocon s Breakthrough Innovation For Psoriasis Treatment PRESS MEET Bangalore, August 10, 2013 Autoimmune Diseases are on the Rise Globally Autoimmune Disease Segment includes
More informationOutlook of China Biopharmaceutical Outsourcing Market
中 国 生 物 医 药 外 包 市 场 前 景 分 析 Outlook of China Biopharmaceutical Outsourcing Market JZMed, Inc. Report Description Attracted by the fast growth of the Chinese biopharmaceutical market as well as the thriving
More informationCommunication and Engagement Strategy 2014 2017. Final Version 30 th June 2014
Communication and Engagement Strategy 2014 2017 Final Version 30 th June 2014 Contents Introduction 4 Strategic Objectives and Role of Communications 6 Communications now and by 2017 7 Communications and
More informationFast Trak Training & Education
GE Healthcare Life Sciences Fast Trak Training & Education Our expertise, your advantage imagination at work Contents General course information General course information 3 Upstream processing Advanced
More informationExciting Trends in Bioprocessing
Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing
More informationTriskel: a strategic consulting firm for biopharmaceutical companies
BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland
More informationChallenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies
Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com
More informationProcess Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases
More informationGE Healthcare Life Sciences. An environmental life cycle assessment comparison of single-use and conventional bioprocessing technology
GE Healthcare Life Sciences An environmental life cycle assessment comparison of single-use and conventional bioprocessing technology An environmental life cycle assessment comparison of single-use and
More informationConsiderations Impacting the Make vs. Buy Decision
Considerations Impacting the Make vs. Buy Decision Thomas C. Ransohoff BioProcess Technology Consultants, Inc. INTRODUCTION AND BACKGROUND D ecisions related to manufacturing are among the most important
More informationOne. Invest with confidence Smart Solar Inverter Solutions. solarinvertersolutions.com. Residential, commercial and large scale applications
MAKING MODERN LIVING POSSIBLE Invest with confidence Smart Solar Inverter Solutions Residential, commercial and large scale applications One inverter supplier of reliable, flexible and user friendly inverter
More informationChallenges and Opportunities of Monoclonal Antibody Manufacturing in China
BioPharma Antibody Therapeutics News Digest Challenges and Opportunities of Monoclonal Antibody Manufacturing in China Chris Chen Introduction About the Author: Dr. Chris Chen is currently Chief Operating
More informationAdvances in Biopharmaceutical and Vaccine Manufacturing Plants
Hitachi Review Vol. 62 (2013), No. 4 267 Advances in Biopharmaceutical and Vaccine Manufacturing Plants Sei Murakami, Dr. Eng. Haruo Suzuki Keisuke Shibuya, Dr. Sc. OVERVIEW: The development of innovative
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationAdvancements in Modularization
Advancements in Modularization Standardization, Modular Unit Operations and Global Deployment Interphex 2013 New York, NY Pär Almhem President ModWave & ModularPartners Outline Introduction to Modularization
More informationIndustrialization of mab production technology The bioprocessing industry at a crossroads
REVIEW review 1:5, 443-452; September/October 2009; 2009 Landes Bioscience Industrialization of mab production technology The bioprocessing industry at a crossroads Brian Kelley Bioprocess Development;
More informationProduction in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation
Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.
More informationNUVISAN Pharma Services
NUVISAN Pharma Services CESI MS Now available! 1st CRO in Europe! At the highest levels of quality. LABORATORY SERVICES Equipment update STATE OF THE ART AT NUVISAN CESI MS Now available! 1st CRO in Europe!
More informationSTRATEGIC WORKFORCE PLANNING LATEST TRENDS AND LEADING PRACTICE EXAMPLES
STRATEGIC WORKFORCE PLANNING LATEST TRENDS AND LEADING PRACTICE EXAMPLES BERLIN, 21 MAY 2015 Julia Howes Mercer Workforce Analytics & Planning A WORKFORCE TSUNAMI IS APPROACHING COPYRIGHT MERCER 2015 STRATEGIC
More informationHUBER Vacuum Rotation Membrane VRM Bioreactor
HUBER Vacuum Rotation Membrane VRM Bioreactor VRM The rotating plate membrane for clean water applications. The future-oriented solution designed for the ever increasing requirements in wastewater treatment
More informationESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES. Dr Andrew Racher
ESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES Dr Andrew Racher Lonza Biologics plc, 2004 Structure of talk Issues Selection of a high producing cell line Selection for process compatibility
More informationA new, integrated, continuous purification process template for monoclonal antibodies
A new, integrated, continuous purification process template for monoclonal antibodies Alex Xenopoulos* Alison Dupont, Christopher Gillespie, Ajish Potty, Michael Phillips Processing Technologies Merck
More informationHow single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs
WHITE PAPER 7004 How single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs By John Boehm Business Unit Manager Colder Products Company Today s
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationProject, Programme and Portfolio Management Delivery Plan 6
Report title Agenda item Project, Programme and Portfolio Management Delivery Plan 6 Meeting Performance Management and Community Safety Panel 27 April 2009 Date Report by Document number Head of Strategy
More informationIBM asset management solutions White paper. Using IBM Maximo Asset Management to manage all assets for hospitals and healthcare organizations.
IBM asset management solutions White paper Using IBM Maximo Asset Management to manage all assets for hospitals and healthcare organizations. September 2007 2 Contents 2 Executive summary 3 Introduction
More informationSimulation Why? Textmasterformate durch Klicken bearbeiten The planning of a biopharmaceutical facility requires the
Simulation Projects The planning of a biopharmaceutical facility requires the Simulation Why? consideration of various interdependent factors. A process simulation can help to optimise an existing process
More informationReaching CMM Levels 2 and 3 with the Rational Unified Process
Reaching CMM Levels 2 and 3 with the Rational Unified Process Rational Software White Paper TP174 Table of Contents INTRODUCTION... 1 LEVEL-2, REPEATABLE... 3 Requirements Management... 3 Software Project
More informationIBM SmartCloud for Service Providers
IBM SmartCloud for Service Providers Launch new cloud services simply and quickly to increase revenue Highlights Offers a pre-integrated, pre-configured, building-block approach to cloud services delivery
More informationGain efficiency in your process development with ÄKTA avant
Gain efficiency in your process development with ÄKTA avant gelifesciences.com Gain efficiency in your process development with ÄKTA avant Development of efficient manufacturing processes is a necessity
More informationOptimize Your Process Operations by Improving Process Monitoring
Integral Process Ana Optimize Your Process Operations by Improving Process Monitoring All industrial processes have a common need reliable, accurate, and timely methods for analyzing process chemistry.
More informationAnimal Pharming: The Industrialization of Transgenic Animals December 1999
Animal Pharming: The Industrialization of Transgenic Animals December 1999 Animal pharming, the process of using transgenic animals to produce human drugs, is staking its claim in a lucrative world market.
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More informationSingle-use bioprocessing
FOCUS ON... DISPOSABLES Upstream Single-Use Bioprocessing Systems Future Market Trends and Growth Assessment by Ronald A. Rader and Eric S. Langer Single-use bioprocessing equipment has become wellaccepted
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationModern inventory management systems: pricing models and market review
Research Report Modern inventory management systems: pricing models and market review January 2014 Mark H. Mortensen and John Abraham 2 Contents Slide no. 6. Executive summary 7. Executive summary 8. The
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationHow To Get A Cloud Computing Diploma
Executive Diploma in Cloud Computing Innovation Achieve More We encourage our students to challenge their thinking, to extend their boundaries, to strive for excellence. We create a positive environment
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationOptimizing Global Engineering Efficiency With a Holistic Project Approach
Optimizing Global Engineering Efficiency With a Holistic Project Approach When executing global projects, engineering companies have to meet challenging requirements from their customers to implement projects
More informationAdvanced Biopharmaceutical Manufacturing: An Evolution Underway
Life Sciences Advanced Biopharmaceutical Manufacturing: An Evolution Underway Executive summary The past decade has seen a significant shift in the nature of the products being manufactured and sold by
More informationLife Cycle Management for Oracle Data Integrator 11 & 12. At lower cost Get a 30% return on investment guaranteed and save 15% on development costs
Life Cycle Management for Oracle Data Integrator 11 & 12 Increase productivity Stop wasting your time doing things maually by automating every step in your project s Life Cycle At lower cost Get a 30%
More informationiccp MBA International Certified Credit Professional MBA www.aicd.global
iccp iccp Programme www.aicd.global Architected by the Association of International Credit Directors (AICD) in conjunction with The Open University 1 iccp These are the critical questions that will help
More informationPORTABLE CONVEYOR SYSTEM
PORTABLE CONVEYOR SYSTEM MINIVEYOR A WORLD LEADER IN SUPPLYING CONFINED SPACE EQUIPMENT TO THE CONSTRUCTION, BUILDING, LANDSCAPING AND EVEN THE MINING INDUSTRY. OUR AIM IS TO SUPPLY A CUSTOMER SERVICE
More informationProviding Trusted and Innovative Solutions t o the Life Science Communities
Providing Trusted and Innovative Solutions t o the Life Science Communities Eurogentec Eurogentec is a leading supplier of trusted and innovative reagents, kits, specialty products and custom research/development
More informationAccelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development
Pharma&Biotech Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development James Rance PhD Head of Development Services Singapore Lonza Biologics
More informationIntroduction to Bioprocessing
Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology
More informationWHAT IS ENTERPRISE OPEN SOURCE?
WHITEPAPER WHAT IS ENTERPRISE OPEN SOURCE? ENSURING YOUR IT INFRASTRUCTURE CAN SUPPPORT YOUR BUSINESS BY DEB WOODS, INGRES CORPORATION TABLE OF CONTENTS: 3 Introduction 4 Developing a Plan 4 High Availability
More informationEMABling Antibody Production Platform
EMABling Antibody Production Platform An industrial solution for the production of therapeutic antibodies with high cytotoxic activity B IOMANUFACTURING EMABling : A fully integrated development platform
More informationMethod Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates
Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates Paula Hong and Kenneth J. Fountain Waters Corporation, 34 Maple St., Milford, MA, USA APPLICATION
More informationCatalent Biologics & Clinical Supplies The SMART Solution
Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany
More informationEfficient, Flexible Facilities for the 21st Century
F l e x-faci liti es disposables Efficient, Flexible Facilities for the 21st Century by Howard L. Levine, Jan E. Lilja, Rick Stock, Hans Hummel, Susan Dana Jones A number of recent improvements in the
More informationBioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma
BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma 2 Novozymes solutions dedicated to the biopharmaceutical industry
More informationThe Index Inside: The Next Evolution of TMS Business Intelligence
ARC BRIEF NOVEMBER 2010 The Index Inside: The Next Evolution of TMS Business Intelligence By Adrian Gonzalez Summary The ability to make smarter decisions faster is what will differentiate tomorrow s industry
More informationWhite. Paper. Extracting the Value of Big Data with HP StoreAll Storage and Autonomy. December 2012
White Paper Extracting the Value of Big Data with HP StoreAll Storage and Autonomy By Terri McClure, Senior Analyst and Katey Wood, Analyst December 2012 This ESG White Paper was commissioned by HP and
More informationBIOTECH MANUFACTURING SOLUTIONS 4 YOUR SUCCESS. a Novartis company
a Novartis company BIOTECH MANUFACTURING Sandoz GmbH Biotech Cooperations 6250 Kundl Austria Biochemiestrasse10 Phone +43 (0)5338 200 2609 Fax +43 (0)5338 200 442 biotech.cooperations@sandoz.com www.sandoz.com
More information"Small and large molecules bioproduction by mammalian and microbial fermentation"
"Small and large molecules bioproduction by mammalian and microbial fermentation" H.-P. Meyer Bio/PharMOS 2004-23-25 March 2004 Symposium B Business Diversification in Life Science "Small and large molecules
More informationExecutive Diploma in Big Data Management & Analytics
Executive Diploma in Big Data Management & Analytics Achieve More We encourage our students to challenge their thinking, to extend their boundaries, to strive for excellence. We create a positive environment
More informationEMC ISILON OneFS OPERATING SYSTEM Powering scale-out storage for the new world of Big Data in the enterprise
EMC ISILON OneFS OPERATING SYSTEM Powering scale-out storage for the new world of Big Data in the enterprise ESSENTIALS Easy-to-use, single volume, single file system architecture Highly scalable with
More informationChoosing Planning & Scheduling solutions for Metals
Choosing Planning & Scheduling solutions for Metals White Paper The planning and scheduling of metals production presents special problems because of the complexity of the manufacturing process and the
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More informationKnowing the customer: this time it s personal. How analytics can help banks achieve superior CRM, secure growth and drive high performance
Knowing the customer: this time it s personal How analytics can help banks achieve superior CRM, secure growth and drive high performance Table of Contents Introduction How advanced analytics changes customer
More informationGovernment Communication Professional Competency Framework
Government Communication Professional Competency Framework April 2013 Introduction Every day, government communicators deliver great work which supports communities and helps citizens understand their
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationINTRODUCING TALEO 10. Solutions Built for the Talent Age. Powering the New Age of Talent
TALEO10 TA LEO.COM Solutions Built for the Talent Age Business value is no longer defined by tangible assets. It s powered by people and ideas. Competitive advantage comes from superior talent driving
More informationAccenture Parts Optimization: Warranty Services Gaining Control Over Warranty Costs
Accenture Parts Optimization: Warranty Services Gaining Control Over Warranty Costs 2 Accenture Warranty Optimization Services: Gaining Control Over Warranty Costs The numbers are compelling: On average,
More informationDeveloping a new generation of business leaders
Executive Route Developing a new generation of business leaders WORKING TOGETHER TO DRIVE SUSTAINABLE BUSINESS TRANSFORMATION The One Planet MBA 1 Working in partnership with WWF International and a range
More informationORACLE PROJECT MANAGEMENT
ORACLE PROJECT MANAGEMENT KEY FEATURES Oracle Project Management provides project managers the WORK MANAGEMENT Define the workplan and associated resources; publish and maintain versions View your schedule,
More informationORACLE PROJECT PLANNING AND CONTROL
ORACLE PROJECT PLANNING AND CONTROL (Formerly Oracle Project Management) KEY FEATURES COLLABORATIVE PROJECT PLANNING Define a project work breakdown structure to align plans to execution Coordinate financial
More informationService Suite for Communications Mobile workforce management solutions
Service Suite for Communications Mobile workforce management solutions No other mobile workforce management provider knows the communications industry like ABB. That s why ABB has become one of the leading
More informationBioProcessing J O U R N A L. Trends and Developments in BioProcess Technology. Volume 9 Issue 1 ISSN 1538-8786
A Production of ISBioTech Summer 2010 Issue BioProcessing J O U R N A L Trends and Developments in BioProcess Technology Volume 9 Issue 1 ISSN 1538-8786 Trends & Developments in BioProcess Technology Novel
More informationPORTFOLIO, PROGRAMME & PROJECT MANAGEMENT MATURITY MODEL (P3M3)
PORTFOLIO, PROGRAMME & PROJECT MANAGEMENT MATURITY MODEL (P3M3) 1st February 2006 Version 1.0 1 P3M3 Version 1.0 The OGC logo is a Registered Trade Mark of the Office of Government Commerce This is a Value
More informationMonoclonal Antibody Therapy: Innovations in Cancer Treatment. James Choi ENGL 202C
Monoclonal Antibody Therapy: Innovations in Cancer Treatment James Choi ENGL 202C Treating Cancer with Monoclonal Antibody Therapy Researchers and scientists have been working for decades to find a cure
More informationThe Sievers 900 Series TOC Analyzers
GE Water & Process Technologies Analytical Instruments The Sievers 900 Series TOC Analyzers imagination at work Delivering Next-Generation Ease of Use, Productivity, and Reliability The Sievers* 900 Series
More information